



Citi Pharma Limited

Date: October 16, 2026

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi

MATERIAL INFORMATION

SUBJECT: RECEIPT OF CCP AUTHORIZATION FOR PROPOSED ACQUISITION OF 100% SHAREHOLDING OF PAKHEIM INTERNATIONAL PHARMA (PRIVATE) LIMITED

In accordance with Section 96 of the Securities Act, 2015 and the applicable provisions of the Rule Book of Pakistan Stock Exchange Limited, Citi Pharma Limited ("the Company") hereby informs its shareholders and the general public that the Company has received the order dated **October 9, 2026**, passed by the Competition Commission of Pakistan ("CCP") in Case No. **1614/Merger-CCP/2026**, authorizing the proposed acquisition of 100% shareholding of Pakheim International Pharma (Private) Limited under Section 31(1)(d)(i) of the Competition Act, 2010.

The said authorization follows the CCP's review of the proposed transaction and its determination that the transaction does not raise competition concerns.

The acquisition shall proceed in accordance with the terms of the Share Purchase Agreement dated May 6, 2026, and upon completion of the applicable legal, regulatory and other formalities. The Company shall make further disclosures, as required, upon completion of the relevant transaction milestones.

For and on behalf of
Citi Pharma Limited

Muhammad Rasheed Alam
Company Secretary



588 - Q, Johar Town, Lahore - Pakistan



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory: +92. 49. 4510189, +92. 49. 4513392



www.citipharma.com.pk